1. France Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Abivax S.A.

Abivax S.A.

AAVXF
Abivax S.A.US flagOther OTC
89.30
USD
+18.04
- -
7.12BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.01
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.64
-0.55
-1.64
-1.47
-1.13
-1.55
-2.51
-2.62
-2.75
-3.18
-3.43
-2.78
-4.83
-4.63
Free Cash Flow per Basic Share
- -
-0.36
-1.64
-1.68
-0.95
-1.51
-2.33
-2.14
-2.92
-2.84
-2.26
-2.44
-2.32
-2.49
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-0.54
-2.15
-3.62
-4.68
-6.1
-7.61
-2.61
-5.28
-7.5
-6.56
-6.92
-10.61
-10.64
Tangible Book Value per Share
0.14
0.21
4.08
2.54
1.63
0.26
-1.11
-0.99
-0.4
-0.93
3.97
0.25
6.19
5.64
Basic Weighted Avg Shares
9
9
10
10
10
10
12
14
15
19
43
63
70
72
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-10,003.64
-36,107.14
- -
-14,359.06
-141,500
-106,166.67
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
Net Income, GAAP
-6
-5
-16
-14
-11
-16
-31
-38
-42
-61
-148
-176
-336
-332
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-7,970.18
-36,285.71
- -
-11,266.14
-112,230
-87,905.56
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
3
4
39
24
15
12
6
18
43
-15
198
78
488
451
LT Debt
2
- -
- -
- -
- -
11
21
34
35
9
27
54
1
- -
Total Equity
34
34
72
57
48
35
19
18
26
7
196
41
455
430
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
29
1
1
LT Borrowings
16
- -
- -
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
78
79
79
Market Capitalization
4,886
6,738
7,185

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
619
551
513
Cash, Cash Equivalents & STI
590
530
492
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
79
63
62
Payables & Accruals
33
45
32
ST Debt
29
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
342.74%
708.3%
1,021.64%
Free Cash Flow
32.6%
41.94%
4.24%
Net Income, GAAP
43.46%
61.87%
90.7%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.68
-0.62
-0.87
- -
-2.78
2025
-0.83
-0.76
-2.1
- -
-4.83
2026
-0.61
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Marc de Garidel
Full Time Employees
69
Sector
Healthcare
Industry
Biotechnology
Address
5, rue de la Baume Paris France 75008
IPO Date
Sep 27, 2016
Website
abivax.com
Similar Companies
Biocon Limited (BIOCON.NS)
InflaRx N.V. (IFRX)
MorphoSys AG (MPSYF)
Tetra Bio-Pharma Inc. (TBP.TO)
Impel Pharmaceuticals Inc. (IMPL)
BridgeBio Oncology Therapeutics Inc. (BBOT)
Business
Abivax S.A. Abivax SA (Nasdaq: ABVX, Euronext Paris: ABVX) is a clinical-stage biotechnology company that develops therapeutics harnessing microRNA-124 to modulate the immune response in patients with chronic inflammatory diseases. The company focuses on obefazimod, an oral small molecule that enhances miR-124 expression for treating moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD); its pipeline includes the ABTECT Phase 3 program in UC, with positive top-line 8-week induction results announced in Q3 2025 and 44-week maintenance data expected in Q2 2026, alongside the ENHANCE-CD Phase 2b trial in CD initiated in Q3 2024 with induction data anticipated in 2H 2026; Abivax also advances follow-on compounds from its proprietary chemical library targeting additional inflammatory indications. Founded in 2013 and headquartered in Paris, France, with R&D in Montpellier, France, and a U.S. office in Waltham, Massachusetts, the company conducts operations across North America, Europe, Latin America, and Asia Pacific through over 600 global study sites. Recent developments include a $747.5 million public offering priced in July 2025, full exercise of the underwriters' option for additional American Depositary Shares, debt conversions by Heights Capital Management and Kreos Capital, joining the CAC Mid 60 index, and acceptance of late-breaking abstracts on ABTECT results at the 2025 United European Gastroenterology Meeting.